President Donald Trump has unveiled TrumpRx.gov, calling it a major step toward lowering prescription drug costs. The White House says the platform could reduce prices of some medications by “as much as 80 percent.” Officials describe the launch as a response to years of frustration over high out-of-pocket costs and argue that Americans have paid an “unfair premium” compared to patients in other developed nations. The administration presents TrumpRx as a tool to bring transparency and direct price comparison to consumers.
At the center of the program is the Most-Favored-Nation (MFN) pricing model. Under this framework, drug manufacturers agree to offer U.S. patients the same or lower prices than those in comparable countries. The White House says this approach ends a system in which Americans “routinely paid more than patients overseas for the same treatments.” Participation is voluntary but encouraged through increased visibility and streamlined access on the platform.
TrumpRx does not dispense medication. Instead, it acts as a digital hub where users can search for drugs, compare prices, and connect with companies offering MFN-aligned discounts. The administration says the structure reduces reliance on intermediaries and focuses on “immediate relief rather than long-term projections alone.”
The first phase targets high-cost brand-name drugs, especially GLP-1 medications for diabetes and weight loss, as well as fertility treatments. Officials cite examples like Ozempic, Wegovy, and Zepbound, which they say have dropped from over $1,000 per month to the mid-$300 range under new agreements.
President Trump has urged Congress to pass a broader “Great Healthcare Plan” to make MFN pricing permanent. The Department of Health and Human Services reports that more than 40 manufacturers have joined so far. Supporters call it patient-focused reform, while critics question enforcement and long-term impact.
